Develops cancer drugs for leukemia and myelofibrosis patients.
Jun 2026Revenue $252M/yrExpenses $446M/yr
No trendCash runway ≈ 2.5 years from Jun 2026
Figures by year
When will Syndax Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $252M and expenses $446M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $172M | $445M | −$273M |
| Dec 2024 | $23.7M | $363M | −$340M |
| Dec 2023 | $0.00 | $230M | −$230M |
| Dec 2022 | $0.00 | $152M | −$152M |
| Dec 2021 | $140M | $113M | $26.2M |
| Dec 2020 | $1.52M | $72.9M | −$71.4M |
| Dec 2019 | $1.52M | $59.1M | −$57.5M |
| Dec 2018 | $1.52M | $77.4M | −$75.9M |
| Dec 2017 | $2.11M | $64.1M | −$62.0M |
| Dec 2016 | $1.22M | $45.0M | −$43.8M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.